On the back of the positive preclinical results and the recent $30 million financing round, Ayala is ready to start a phase 2 study of AL101 in TNBC. Separately, the drug is in a phase 2 trial in adenoid cystic carcinoma, with an FDA orphan drug designation.
Ayala’s ex-BMS drug shows promise in triple-negative breast cancer
![](https://ibf.fund/wp-content/uploads/2019/01/Screen-Shot-2017-12-18-at-10.48.14-copy-e1547130272327-500x300.png)